background: Timing of natural menopause has great implications for fertility and women's health. Age at natural menopause (ANM) is largely influenced by genetic factors. In the past decade, several genetic studies have been conducted to identify genes in ANM, which can help us unravel the biological pathways underlying this trait and the associated infertility and health risks. After providing an overview of the results of the genetic studies performed so far, we give recommendations for future studies in identifying genetic factors involved in determining the variation in timing of natural menopause.
Introduction
Implications of menopausal age on fertility and women's health Throughout the last decades the interest in the mechanisms behind ovarian ageing and the timing of natural menopause has increased since menopause has great implications for women's fertility and health. The gradual decline in female fertility with age has been long known from several sources (Menken et al., 1986; Evers 2002; Kok et al., 2003) . As a result of an increase in the number of educated woman, growing participation of women in the labour market together with the wide availability of reliable contraception methods, women have been postponing childbirth in recent decades (Leridon, 2006) . This tendency of postponed childbearing has consequently led to an increase in age-related infertility, subsequently increasing the utilization of assisted reproductive technologies (ART) and unwanted childlessness (Menken et al., 1986; ESHRE Capri Workshop Group, 2005; Leridon and Slama, 2008; Broekmans et al., 2009 ). An increase in the overall uptake of ART causes a financial burden to society as well as a large emotional impact on the couples that are faced with fertility problems. With the ability to predict age at menopause, and thus the end of the reproductive lifespan for an individual woman, family planning and fertility treatment could be greatly influenced (te Velde et al., 1998; Broekmans et al., 2007) .
Besides fertility implications, menopause is linked to a variety of health risks (Ossewaarde et al., 2005) . Early menopause is associated with a higher risk of cardiovascular disease (van der Schouw et al., 1996; Hu et al., 1999; Mondul et al., 2005; Atsma et al., 2006; Lisabeth et al., 2009 ) and osteoporosis (Kritz-Silverstein and Barrett-Conor, 1993) , whilst a late menopause age has been associated with an increased risk of breast cancer (La Vecchia et al., 1992) .
Menopausal age as a complex genetic trait
Menopause occurs when the follicle pool in the ovaries has become exhausted and is insufficient to maintain menstrual cycles. Menopause therefore marks the definitive end of a woman's reproductive lifespan (Faddy and Gosden, 1996) . The age at natural menopause (ANM) varies widely amongst women and ranges roughly from 40 to 60 years of age (Treolar et al., 1981; te Velde and Pearson 2002) . Although the exact physiological processes underlying the timing of menopause are far from elucidated at present, genetic factors have proven to play a major role in determining this variation in menopausal age, as demonstrated in several mother -daughter, twin and sib-pair studies. Estimations of heritability in menopausal age range from 31 to 87% (Torgerson et al., 1997b; Snieder et al., 1998; de Bruin et al., 2001; van Asselt et al., 2004; Murabito et al., 2005a) . This wide range in heritability estimates of ANM reflects the difficulty of measuring heritability for this trait. Besides this, heritability estimates cannot be used to assess the magnitude of the genetic contribution to a trait (Vitzthum, 2003; van Asselt et al., 2006) . This is because the components of the variance, genes and environment, are in most cases not independent, but interactive. Causes of phenotypic variation cannot be separated into genes and environment, and the different genetic and environmental components cannot simply be summed up to 100%. In addition, genetic variance comprises different types (i.e. additive, dominant and epistatic variance) resulting in incomparable heritability estimates from parent -offspring and twin heritability studies. Next to multiple genetic factors, several environmental and life-style factors like smoking, body mass index, use of alcohol and parity have claimed to influence menopausal timing as well, although the effects seem small and been inconclusive (Bromberger et al., 1997; Torgerson et al., 1997a; van Noord et al., 1997; Kato et al., 1998; Gold et al., 2001; Kok et al., 2005a; Parente et al., 2008) .
Thus menopausal age is a complex genetic trait. Identification of the environmental factors and genes that contribute to the endowment and wastage of follicles in the ovaries and thus timing of menopause will add to the understanding of the physiological mechanism of this trait and the associated infertility and health risks. Various research groups have carried out genetic studies in ANM cohorts using a candidate-gene and genome-wide approach, including both a linkage mapping and association design. In this paper we will review the current status of genetic studies conducted on ANM in humans. Before summarizing the current published literature, the basis of genetic analysis for complex genetic traits will be presented. After providing an overview of the results of the association studies and subsequent replication studies performed thus far, we aim to give recommendations for future studies to identify genetic factors involved in determining the variation in timing of natural menopausal age.
Genetic approaches in determining age at natural menopause
In order to elucidate the loci or genes involved in complex traits, like the timing of ANM, the three most commonly used genetic approaches are: genome-wide linkage analysis, candidate gene association studies and genome-wide association studies (GWAS). The designs of all these three types of genetic epidemiologic studies have been described extensively in other papers (Burton et al., 2005; Teare and Barrett, 2005; Kraft and Cox, 2008) , and will be briefly summarized below.
Genome-wide linkage analysis
In linkage analyses, genetic loci that contribute to a trait can be identified using a set of (genome-wide) genetic markers in related individuals. Linkage occurs when loci are transmitted together from parents to their offspring more often than expected under independent inheritance. If a marker can be identified that is passed down through a family such that it consistently accompanies the disease or trait of interest, this suggests that a genetic variant, with a functional effect on a disease or distinct trait (such as height or menopausal age), is located in the region surrounding the marker (linkage region) (Lander and Kruglyak, 1995; Burton et al., 2005) . Using mathematical models it is possible to estimate the evidence for linkage in a certain genetic region. In these models, the recombination fraction is important and indicates the probability of recombination between two loci, i.e. the separation of the two loci due to crossing over of homologous chromosomes. The further apart two loci are, the higher the chance that there will be recombination with a maximum of 50% (Burton et al., 2005) . So a recombination fraction ,0.5 indicates that the chance of recombination between two loci is less than 50%.
Usually the LOD (logarithm of odds) score is used as an estimate for the evidence of linkage. The LOD score is a function of the recombination fraction. A LOD score .3 is generally accepted as significant evidence of linkage, whereas a LOD score less than 22 is regarded as significant evidence against linkage.
After significant linkage regions are found, extensive candidate gene studies are required to identify the causal genes for a trait within this linkage region (see: candidate gene association studies, below). Genetic linkage approaches have been particularly successful for the identification of genes underlying monogenetic diseases. However, in complex traits where several genes and environmental factors contribute to the trait, there is no clear mode of inheritance. Although methods for model-free linkage analysis exist, these methods have not been very successful in the identification of genes that play a role in complex traits. The most important reason for this is lack of statistical power. Thus, linkage analysis is less suitable for identifying genes in this type of traits (Altmüller et al., 2001; Burton et al., 2005; Lamberts and Uitterlinden, 2009) .
Candidate gene association studies
Analysis of the association between a genetic variant and a trait is in fact the traditional epidemiologic disease-exposure association analysis applied to genotypes or alleles in a population (Burton et al., 2005) . This method can be applied to candidate genes, or genome wide. In this part, we will discuss the principles of a candidate gene association study.
Candidate genes are genes that are believed to influence complex traits due to their expected involvement in the biological pathway of that trait, or to their location near a region previously determined in a linkage analysis of the trait. Thus candidate genes are selected based on at least some knowledge about the physiology of the examined trait. Next, genetic variants are selected within the gene that are then associated with the trait. Several types of genetic variation can be studied, the most common one being single nucleotide polymorphisms (SNPs), which are DNA variants that represent variation in a single nucleotide (A, T, C or G). When candidate gene studies were first performed, SNPs were often chosen because of their effect on amino acid change (referred to as non-synonymous SNPs). However, there are also other types of SNPs, such as synonymous SNPs in protein-coding regions (which do not result in amino acid changes) and SNPs in introns or intergenic regions. All types of SNPs may influence complex traits or diseases as they may, for instance, cause variation in gene regulation and expression or differential splicing (Cordell and Clayton, 2005) . With the completion of the first phase of the HapMap project, information on many SNPs in the human genome became available. Because of this large amount (which is still growing) it is impossible to predict which variants will be functional. As a result, the field moved towards indirect association studies. In this type of study the SNP is a proxy for a causal variant (Cordell and Clayton, 2005) . Due to correlations between SNPs (linkage disequilibrium, LD), it is possible to identify total genetic variation in a gene without genotyping every SNP. In this so-called tagging SNP approach, the fact that SNPs are passed on to the next generation in fixed non-recombining blocks of genetic information is used. This means that with a limited number of SNPs the total genetic variation in that block can be described by just a few tagging SNPs (Johnson et al., 2001; Hirschhorn and Daly, 2005) .
Genome-wide association studies
Since the publication of the International HapMap Consortium (2005), a public database containing common genetic variants (allele frequency 1%) is now generally available. Furhtermore, reduced genotyping costs in recent years have made it feasible to perform GWAS. A GWAS investigates genetic variations underlying a trait or disease that can be explored without prior assumptions on biological pathways and physiology. This is in contrast to association studies using candidate gene studies where prior assumptions on biological pathways are needed. However, it is often stated that GWAS is a hypothesisfree search, which is not the case. In fact GWAS are based on the common disease, common variant hypothesis (Lander, 1996; Hirschhorn et al., 2002) . Therefore, nowadays people refer to it as an agnostic scan.
In GWAS around 500 000 SNPs are genotyped. These SNPs were chosen to best cover the genetic variation of the entire genome and are mostly tagSNPs. Thus these SNPs were not chosen on the basis of their possible functional effects.
In the last few years, an exploding number of GWAS have been published. Although not all GWAS hits could be replicated, the results illustrate that an agnostic scan of the entire human genome can produce findings that would have been missed with candidate gene approaches. Also, the GWA findings can lead to new hypotheses on the aetiology of complex traits.
Methods
The electronic databases of MEDLINE (Pubmed) and Embase were searched for English-language articles until September 2009, using the keywords: 'menopause' and 'age at menopause' in combination with the keywords: 'genetics', 'polymorphism', 'candidate gene', 'association study' or 'genome wide'. In addition, we had searched related articles and reference lists of selected studies on the subject for other relevant articles. We included all articles on genome-wide linkage mapping and genome wide or candidate gene association studies in timing of natural menopausal age as a single end-point or natural menopausal age as part of a number of reproductive determinants without any selection on quality criteria (Fig. 1) , as in that case too few studies would have remained.
Results
A total of 28 papers on genetics in ANM emerged from our literature search: two papers on genome-wide linkage analysis, 23 papers on association studies using candidate genes and another three papers on GWAS.
All studies used the WHO definition of menopause (12 consecutive months of amenorrhea not due to surgery or other obvious causes) in determining ANM (World Health Organisation Scientific Group, 1996) . Also, all 28 studies determined ANM through selfreportage by either in-person interviews or questionnaires.
Genome-wide linkage analysis
Two genome-wide linkage analyses on ANM have been published to date (Table I) . Van Asselt et al. conducted the first study in 2004 in a population of 579 extremely discordant and concordant sib-sister pairs from 165 families. The study subjects were genotyped for a total of 417 microsatellite markers. Two regions showed suggestive linkage with ANM: region Xp21.3 (LOD score 3.1) and region 9q21.3 (LOD score 2.6) . The observed linkage region on the X chromosome has also been described as a linkage region in premature ovarian failure (POF), which is defined as the onset of menopause under the age of 40 (Toniolo, 2006) . After exclusion of women with a menopausal age less then 40 years of age, the linkage peak attenuated, although suggestive linkage of the region remained. This implies that the Xp21.3 region not only influences premature menopause, but might also affect early menopause and/or menopausal age as a whole. The linkage region on chromosome 9 contains multiple genes, of which one gene that encodes for a protein of the BCL2 family is particularly interesting. This protein is known for its involvement in apoptosis, and the rate of apoptosis in the ovarian follicle pool could well play a role in determining onset of menopause (Billig et al., 1996) . The BCL2 encoding gene could therefore be a possible contributing candidate gene for ANM (Hsu et al., 2000) . To date, as far as we are aware, no additional studies on BCL2 in association with ovarian ageing have been published.
In 2005, a second genome-wide linkage study was carried out in a population-based sample of 861 post-menopausal women from 291 families. Genotyping was performed with a genome-wide scan of 401 microsatellite markers. In the unadjusted analysis, two suggestive linkage regions for ANM appeared: chromosome 8 at 26 centimorgan (cM) (LOD score 2.6) and chromosome 16 at 11cM (LOD score 2.4). After adjustment for body mass index (BMI) and cigarette use, another region with suggestive linkage emerged chromosome 11 at 113 cM (LOD score: 2.1) (Murabito et al., 2005b) . Similar to the linkage study of van Asselt et al., women with early onset of menopause (40 years) were excluded for an additional linkage analysis. As a result the LOD scores lowered, suggesting a role for these loci in premature and/or early menopause. Near the observed linkage peak on chromosome 8 lies the gonadotrophin-releasing hormone 1 gene (GNRH1) at locus 8p21-p11.2. The gonadotrophin-releasing hormone (GnRH) is a key molecule in the hypothalamic -pituitarygonadal axis controlling human reproduction (Marshall and Kelch, 1986) . As the release of follicle-stimulating hormone (FSH) from the pituitary gland is, at least in part, controlled by pulsatile GnRH and the magnitude of FSH exposure may affect the rate of follicle loss (Themmen and Huhtaniemi, 2000) , the GNRH1 gene could be considered as an interesting candidate gene for timing of menopause.
Candidate gene association studies
We found a total of 23 papers on association studies using candidate genes, in which 25 genes were examined on association with ANM. Number of genotyped microsatellite markers.
x Extremely discordant and concordant sib-pairs.
In the 25 studied candidate genes on ANM, the majority of the genes can be divided in two major biological pathways: genes involved in steroid pathways and vascular-function-related genes.
Candidate genes involved in steroid pathways
Estrogen-related genes have been of particular interest in the search for genes influencing ANM, as is shown by the large number of candidate gene studies conducted in the pathway of this particular steroid (Table II) wastage of follicles has so far been attributed to gonadal steroid effects, although a recent publication has suggested the presence of functionally active estrogen receptors in primary follicles in mice (Dharma et al., 2009 ). To date, nine genes involved in estrogen biosynthesis and metabolism have been examined as to their role in timing of menopause. Five genes were reported to be significantly associated with this trait at least once. The first candidate-gene association study on ANM was conducted in 1999 by Weel et al. in the estrogen receptor gene (ESR1). A significant association was found between the PvuII SNP in the estrogen receptor gene (ESR1) and ANM in Caucasian women (Weel et al., 1999) . However, in three subsequent studies this finding concerning the PvuII SNP could not be replicated. Moreover, no associations were found in other studied SNPs in ESR1 (Gorai et al., 2003; Kok et al., 2005b; Dvornyk et al., 2006b ).
In the estrogen-inactivating gene cytochrome P-450 1B1 (CYP1B1), one SNP (rs1800440) was significantly related to ANM in a large population of 1360 Caucasian women . Although that particular SNP was not replicated, three other SNPs (rs100212, rs1056827 and rs1056836), which are not in complete LD with the earlier associated SNP rs1800440, were associated with ANM in a sample of 797 Chinese women (Long et al., 2006) . However, Mitchell et al. could not replicate these associations with ANM found by Long et al. in a small population of 64 Caucasian women (Mitchell et al., 2008) .
Mitchell et al. examined two polymorphisms in the cytochrome P-450 19 gene (CYP19A1), which is involved in estrogen synthesis. In this study of 64 post-menopausal white women the TTTA repeat was associated with ANM; women carrying two CYP19A1 7r(-3) alleles had a 2.6-year later onset of menopause, compared with those with no 7r(-3) alleles (Mitchell et al., 2008) . He et al. also examined the role of CYP19A1. Although they did not include the TTTA repeat polymorphism in their study, they did find an association with ANM in two (rs1065778 and rs2255192) of a total of 28 examined SNPs in this gene (He et al., 2007) . However, after correction for multiple testing, taking the total number of tests into account, these associations were no longer significant.
Next to CYP19A1, the estrogen receptor b gene (ESR2) has also been studied in relation to the timing of menopause. Although no significant association with ANM was found in 17 SNPs in the ESR2 gene, an association was found in two blocks with, respectively, 8 and 9 SNPs in LD with each other (He et al., 2007) . Of note, no other study tried to replicate this association thus far.
Finally, carriers of AG alleles of SNP rs2830 in the estrogensynthesizing gene hydroxysteroid dehydrogenase (HSD17B1) experienced a later menopause compared with those with AA alleles, in a small study population of 64 white women (Mitchell et al., 2008) . Again, to our knowledge, this association has not been examined in subsequent studies.
Four other estrogen-related genes were examined, but no association with ANM was found: the estrogen-synthesizing genes cytochrome P-450 17 (CYP17A1) and 17-b-hydroxysteroid dehydrogenase type 1 (HSD17B1) and the estrogen-inactivating genes catechol-O-methyltransferase (COMT) and cytochrome P-450 1A1 (CYP1A1) (Gorai et al., 2003; Hefler et al., 2005; Kok et al., 2005a; He et al., 2007; Mitchell et al., 2008) .
Other examined candidate genes involved in the steroid pathway are the anti-Müllarian hormone gene (AMH) and AMH type 2 receptor gene (AMHR2). Because AMH inhibits primordial follicle recruitment in ovaries of mice, it was hypothesized that AMH also regulates the ovarian follicle pool in women and therefore could influence menopausal timing. Using single tagSNPs for the AMH and the AMHR2 gene, the total genetic variation in these genes could be described (Kevenaar et al., 2007a) . Only the SNP in the AMHR2 gene was found to be significantly associated with ANM in interaction with parity in a large Caucasian population (Kevenaar et al., 2007b) and was also associated with estradiol synthesis in the dominant follicle in an earlier study (Kevenaar et al., 2007a) .
No association with ANM was observed in other studied steroid-related candidate genes like steroid 5-alpha-reductase type 2 gene (SRD5A2) and FSH receptor gene (FSHR) (Zerbetto et al., 2008) .
Vascular-function-related candidate genes
Based on the hypothesis that vascular ageing and reproductive ageing are connected, a variety of studies have focused on vascular-related candidate genes in association with ANM (Table III) . A later onset of menopause has been associated with an increased risk of cardiovascular disease (van der Schouw et al., 1996; Hu et al., 1999; Mondul et al., 2005; Lisabeth et al., 2009) . Conversely, cardiovascular risk factors may be involved in determining timing of ANM as well . Moreover, it is hypothesized that ageing of the ovarian vasculature influences individual variation in ovarian ageing and consequently plays a role in the individual variation in timing of menopause, making cardiovascular risk factor genes plausible candidate genes for ANM (Kurjak and Kupesic, 1995; Hayward et al., 2000) . Three vascular-related candidate genes have been significantly associated with ANM. Carriers with at least one minor allele of the coagulation factor V Leiden (FV) experienced an earlier onset of menopause Tempfer et al., 2005) , whereas carrying at least one minor allele of the factor VII gene (FVII) would delay menopause (van Disseldorp et al., 2008) . The third gene that was described to be associated with ANM is the apolipoprotein E gene (APOE) (Koochmeshgi et al., 2004; Tempfer et al., 2005; He et al., 2009b) , which is involved in lipoprotein metabolism. However, in subsequent studies the association of FV and APOE with timing of ANM could not be confirmed (van Disseldorp et al., 2008) . No replication study in FVII was performed to date. Finally, in other examined vascular-related genes, like nitric oxide synthase (Nos3), clotting factor II (FII) and angiotensinogen (AGT) no association with ANM was found (Hefler et al., 2002; Worda et al., 2004; Tempfer et al., 2005; van Disseldorp et al., 2008) .
Miscellaneous candidate genes
A few studied candidate genes cannot be classified as vascular or steroid related (Table IV ). An example is the histidine decarboxylase gene (HDC), which is the crucial enzyme for synthesis of histamine in humans. Histamine was found to directly stimulate the secretion of GnRH, which in turn plays an important role in female reproduction (Noris et al., 1995) . Of the 11 examined SNPs in HDC, one SNP was significantly associated with ANM in a population of 265 Caucasian women. Women carrying the T allele of SNP rs854163 were older at menopause compared with non-carriers (Zhang et al., 2006) . No subsequent studies on HDC in relation to ANM were performed.
Furthermore, the interleukin-1 receptor antagonist gene (IL-1RA) that encodes for the cytokine interleukin-1 involved in autoimmune mechanisms was studied as a candidate gene in ANM because of the reported role of autoimmune mechanisms in POF (Tuohy and Altunas, 2007) . In a population of 90 post-menopausal Caucasian women with a mean ANM of 50 years, no association with timing of menopause was found (Riener et al., 2004 ).
Genome-wide association studies
Up until September 2009, one rather small and two large GWAS on ANM have been published (Table V) . The first GWAS was conducted in 2007 as part of a GWAS on longevity-related traits (Lunetta et al., 2007) between the 100K SNPs and ANM while taking into account the correlation among related individuals (Cupples et al., 2007) . Top ranked SNP associations in the GEE model included rs6910534, located on chromosome 6 near the FOrkhead Box O3a (FOXO3a) gene (number 11 in the top ranked SNP; P ¼ 0.00003). FOXO3 functions at the early stages of follicular growth as a suppressor of follicular activation (Castrillon et al., 2003; John et al., 2007) , making it a potential interesting candidate gene in ovarian ageing and thus timing of menopause (Watkins et al., 2006) . Next, in 2009 two large GWAS were published simultaneously (He et al., 2009a; Stolk et al., 2009) . He et al. performed a GWAS in two separate cohorts concerning age at menarche and ANM in a total of 17 438 women. In the joint analysis of the two studies, 13 SNPs reached genome-wide significance for ANM. Of these 13 associated SNPs, 1 SNP is located on chromosome 20p12.3, 6 SNPs on 19q13.42, 5 SNPs on 5q35.2 and 1 SNP on 6p24.2 (He et al., 2009a) .
Stolk et al. included a total of 5465 women, using a two-stage design. Stage 1: baseline GWAS in and stage 2: meta-analysis of 4 association studies on 32 top ranked SNPs from 24 loci found in the baseline GWAS. In the combined stage 1 and 2 analyses, six SNPs reached genome-wide significance for ANM: four SNPs are located on chromosome 19q13.4, one SNP on chromosome 20p12.3 and one SNP on chromosome 13q34 (Stolk et al., 2009) .
There are no overlapping results between the two recent large GWAS and the smaller GWAS conducted in Lunetta et al., 2007. In the two recent GWAS however, overlapping results were reported for chromosome 19q13.42 and 20p12.3, which are located in or near the BR serine threonine kinase 1 gene (BRSK1, also known as SAD1) and the minichromosoma maintenance complex component 8 gene (MCM8), respectively. BRSK1 encodes for AMPK-related kinase (AMPK-RK). The highest expression of BRSK1 is located in the human brain where it is required for neuronal polarization, but intermediate expression in adult ovaries was also detected. In experiments, mice homozygous for deletion of only one BRSK1 gene were healthy and fertile, but double-knockout mice died soon after birth (Kishi et al., 2005) . MCM8 encodes for minichromosome maintenance protein, which is essential for genome replication (Kinoshita et al., 2008) . A possible role for both BRSK1 and MCM8 in reproductive ageing and thus timing in menopause have not yet been investigated and needs further elucidation.
Discussion
The results of the different genetic studies on ANM clearly show the difficulties in finding genetic loci for this complex trait. First, we have been able to identify few, if any, consistent findings among candidate gene association studies. Second, when comparing the different types of studies (i.e. candidate gene studies, linkage analysis and GWAS), there is almost no overlap in the genes that are associated with ANM. Several explanations can be proposed to underlay these inconsistent findings.
Inconsistency among candidate gene association studies
A striking inconsistency among candidate gene association studies on ANM becomes obvious when exploring the data of the studies conducted in the past decade. A number of polymorphisms in various candidate genes have been associated with ANM. However, often no subsequent study was conducted. If a subsequent study had been performed, the initial finding could never be replicated unanimously. Moreover, a few studies even reported conflicting results on the direction of the association between a certain variant with ANM (Weel et al., 1999; Hefler et al., 2005; Kok et al., 2005; Long et al., 2006; Mitchell et al., 2008) . Several possible factors may explain the inconsistent findings in candidate gene association studies. At first, a potential explanation can be found in the heterogeneity of the populations in the different studies. For example, three SNPs within the CYP1B1 gene were found to be positively associated with higher ANM in a Chinese population (Long et al., 2006) . This significant association could not be replicated in a population of Caucasian women (Mitchell et al., 2008) , whereas this study reported a significant association in another SNP in this population. These different results can occur due to differences in allele frequencies and possible discrepancies in the effect of variants on the trait in separate ethnic populations. Also, when studies do not sufficiently account for ethnic differences within their study population, this can lead to the finding of spurious results, a phenomenon referred to as population stratification (Cardon and Palmer, 2003; Freedman et al., 2004; Marchini et al., 2004; Campbell et al., 2005) . Another explanation for inconsistency could be the lack of power caused by limited sample sizes. The sample sizes in our reviewed candidate gene association studies varied widely from 64 to 2381 women. Because it is expected that common genetic variants will only have a small effect on complex traits, small studies will lack the power to detect these common variants, and can therefore falsely claim that the variant is not associated with the disease or trait (false-negative results) (Ioannidis et al., 2003; Lohmueller et al., 2003; Hattersley and McCarthy, 2005) .
A third explanation may stem from the fact that some studies did not adjust for multiple testing and therefore had a higher chance of finding false-positive results. This could explain why these associations could not be confirmed in subsequent studies. For this reason, replication of associated gene variations should be standard performed in these studies (Hattersley and McCarthy, 2005) .
Finally, age at onset of natural menopause can be divided between women with POF (i.e. onset of menopause under 40 years of age), early menopause (EM, i.e. woman with ANM between 40 and 45 years of age) and women who experienced menopause later than 45 years of age. Whether POF cases with no obvious cause (idiopathic POF) may be considered as a genetic entity or to be part of the variation towards EM or even the entire distribution of natural menopause remains unclear. However, observations that women with POF and EM are found within the same families, suggests a genetic relationship between POF and EM (Tibiletti et al., 1999; Vegetti et al., 2000) . So, genes involved in idiopathic POF might also be associated with EM or later menopause Broekmans et al., 2009) . Some reviewed candidate gene association studies excluded women suffering from POF and/or EM from their study population, whereas others made no distinction between the three categories of menopausal age. These differences in study populations might be a reason for finding false-positive or false-negative results and could also be a reason for failure of replication.
For the feasibility of replication in candidate gene association studies, the quality and transparency of the performed studies is essential. In this paper we did not limit the inclusion of studies based on their quality, as for one this would have left us with few studies, and second, not all studies provided enough information to judge their quality. While reviewing the papers concerning a possible association with ANM, we found that basic data regarding methods and results were not always mentioned. Examples of these missing data include ethnic homogeneity of the studied population, in-or exclusion of POF patients, genotyping call rate and the direction of the observed effect on ANM. By transparent and complete reporting of genetic studies, it becomes more feasible to compare results and enhance the development of further studies .
Taking the previous possible reasons for non-association and nonreplication into account, inconsistency of associations between separate studies does not necessarily mean that the reported results were false positive or false negative. Replication therefore remains the key step in candidate gene association studies.
Lack of overlap in the results of linkage analysis, candidate gene and genome-wide association studies
When comparing the results obtained by linkage studies, candidate gene association studies or GWAS, no overlapping genes or loci were observed. A number of factors can possibly explain this lack of overlap in the genetic regions identified as related to ANM.
Difference in study design between linkage analysis and GWAS
None of the suggestive linkage regions that were found in the two genome-wide linkage analyses, also emerged in the two GWAS on ANM. However, since the two designs are based on different assumptions (see introduction) discrepant findings may not come as a surprise and are even to be expected. As explained above, linkage analysis is most suitable for the detection of genes involved in monogenetic traits. Because of the low heritability of most complex traits, linkage analyses are less suitable for these types of traits (Hirschhorn and Daly, 2005) . In addition, the underlying assumption of association studies is the common disease, common variant hypothesis (Lander, 1996; Hirschhorn et al., 2002) . This means that these studies aim at finding a set of common variants that together are involved in the etiology of the trait. At the same time, rare variants with moderate to strong effect may be better detected by linkage analysis (Stein and Elston, 2009 ).
Lack of overlap between candidate gene and genome-wide association studies
Due to a number of reasons, the associated genes in the candidate gene association studies on ANM were not detected in the two conducted GWAS. First, GWAS often do not have enough power to detect genes with small effect sizes because of strict correction for multiple testing (Frazer et al., 2009) . By controlling the false-positive rate in GWAS, the false-negative rate increases. Among the multiple SNPs that do not reach genome-wide significance there will probably still be many genes which are involved in ANM. Therefore, if no significant associations of genetic variants in certain candidate genes are detected, this does not imply that the association found in the candidate gene study was a false positive.
Second, genomic coverage of GWAS genotyping arrays have been estimated to capture up to 80% of common SNP variation in the population (International HapMap consortium, 2007) . Even high-density arrays do not cover all common SNPs and thus may not cover possible causal SNPs for ANM, which could lead to false-negative results (Pearson and Manolio, 2008) .
In addition, reasons that might explain non-replication in candidate gene studies, such as population stratification and lack of power in genes with small-effect sizes, may also represent reasons for inconsistency between candidate gene association studies and GWAS (Cooper et al., 2008) .
Finally, the lack of overlap could be due to the fact that candidate gene association studies may have focused on the wrong pathways, genes or polymorphisms. Selecting candidate genes is notoriously inaccurate because of the often poor understanding of underlying mechanisms of complex traits such as ANM (Hattersley and McCarthy, 2005) . If a candidate gene is selected for a certain trait, susceptible variants possibly influencing the trait need to be identified first. Initial studies have focused on known polymorphisms of a candidate gene preferably with a hypothesized functional effect of the polymorphism (Stein and Elston, 2009 ). However, more and more common variants in the genome have become known, although it was not yet clear whether these genetic variants had any functional implications. It therefore has become custom to also genotype variants for which this information was not yet available (Zondervan and Cardon, 2004; Hattersley and McCarthy, 2005) . The publication of the HapMap data in 2005 enabled researchers to describe the total variation in a gene by using a limited amount of tagSNPs (as described in the Introduction section) (International HapMap Consortium, 2005; Pettersson et al., 2009 ).
Future prospects for genetic research on timing of menopause
Given the lack of consistency between findings within and between the various studies and analytic approaches, essential methodological issues will have to be taken into account in future genetic research.
Until now, genetic studies in ANM have been small and therefore have lacked power to detect genes with small effect sizes. In recent years different study populations have been pooled by the formation of large consortia to increase power (Altshuler et al., 2008; Burton et al., 2009) . Collaboration of study groups has resulted in large studies with dramatically increased power, as seen in the two recent GWAS by He and Stolk on ANM (He et al., 2009a,b; Stolk et al., 2009) . However, attention must be paid to heterogeneity between the studies when pooling the data of multiple study populations (Ioannidis et al., 2003) .
Instead of focusing mainly on common variants, emphasis can be put on rare variants. Candidate gene studies as well as GWAS are based on the assumption that common variants underlay common diseases and traits (Lander, 1996; Hirschhorn et al., 2002) . In addition to these common variants, a significant proportion of the inherited susceptibility to complex common diseases and traits may be due to the summation of the effects of a series of rare variants in different genes (minor allele frequency between 0.1 and 2-3%), known as the rare variant hypothesis (Altshuler et al., 2008; Bodmer and Bonilla, 2008; Gorlov et al., 2008; Frazer et al., 2009) . GWAS and candidate gene association studies are not designed for, or capable of, finding these rare variants (Bodmer and Bonilla, 2008) . In GWAS, indirect mapping is performed using tagSNPs, which probably do not cover rare variants due to weak correlations between them. To associate rare variants with a disease or trait, it is necessary to perform direct mapping, and rare variants within a sample must first be identified by sequencing of candidate genes or entire genomes (Li and Lean, 2009 ). Detection of rare variants becomes feasible because of the availability of low-cost, high-throughput sequencing technology (Solexa). As a result, there is now an increasing interest in the rare variant hypothesis for all sorts of traits, including ANM.
Both for studies on rare variants and for future candidate gene association studies, selection of correct candidate genes is pivotal. In candidate gene studies that have been performed on ANM so far, it is possible that wrong candidates were chosen. Studies have mainly focused on genes involved in steroid pathways and vascular-functionrelated genes, while convincing evidence of involvement of these pathways in ANM is lacking. More probable candidate genes in underlying ANM might be found in pathways involved in cell apoptosis and development of the follicle pool (Elvin and Matzuk, 1998; Ben-Shlomo et al., 2002) . Also, genes emerged from GWAS on ANM could give rise to new pathways in this trait, although the results of the two GWAS performed to date have not provided us with clear pathways from which possible candidate genes can be easily harvested.
The understanding of structural genetic variants like copy number variations, insertion -deletion variants and inversion variants has increased greatly in recent years (Iafrate et al., 2004; Eichler et al., 2007) . Although SNPs are the most prevalent genetic variants in the genome, it has been suggested that structural variants account for at least 20% of all genetic variants and are also likely to contribute to common diseases or complex traits (Stranger et al., 2007; McCarroll, 2008; Frazer et al., 2009) . With growing knowledge of structural variants, and more importantly, increasing technological ability to detect structural variants in the genome, it will become feasible to conduct genome-wide association studies involving structural variants (Frazer et al., 2009) .
Next, it is likely that complex traits are influenced not through single genetic variants alone, but particularly through gene-gene (also referred to as epistasis) and gene -environment interaction (Cordell, 2002) . This suggests the importance of studying joint effects of genes combined with environmental risk factors. Until now, association studies have mainly used single locus analysis, in which one SNP at a time is analyzed, without investigating epistasis and geneenvironment interactions. This has resulted in the growing recognition that multi-locus analysis tools, in which gene-gene, geneenvironment or even higher order interactions are modeled are needed to help elucidate the etiology of complex traits (Wang et al., 2005; Chen et al., 2007) .
Finally, in addition to genetic studies to identify structural genetic variants, epigenetics may help us to elucidate genetic factors underlying common diseases or traits. Epigenetics focuses on heritability that is not related to DNA sequence and that is involved in regulation of gene expression (Feinberg, 2008 ). An example of epigenetic modification is DNA methylation, which has been studied particularly in cancer genetics (Bjornsson et al., 2004) . In recent years, interest in epigenetic approaches in addition to genetic approaches for common diseases and traits has increased. Epigenetic variation might help to explain the quantitative nature of complex traits and diseases as well as the role of environment in their development (Bjornsson et al., 2004) .
Conclusion
Over the recent decades, huge efforts have been made to identify genetic factors underlying timing of natural menopause by conducting linkage analysis, candidate gene association studies and GWAS on the subject. The ultimate end-point of this search is to unravel the biological pathway of ANM and allow for prediction of timing of menopausal age in sufficient advance.
Thus far, linkage analyses have detected a few regions of suggestive linkage with ANM. However, these regions need to be further examined to find the candidate genes underlying these linkage peaks. The candidate gene association studies conducted on ANM in the last decade found very little consistent associations, if any. The recent published results of the two GWAS conducted in ANM have detected potential new genetic loci that may help us in elucidating the physiology of ovarian senescence and thus timing of menopause. Despite all the efforts made in discovering genetics underlying ANM, the overall results have been rather disappointing thus far. In this paper we described possible new strategies that might help us to identify more genetic loci involved in variation in timing of natural menopause.
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